- Home
- SOS vs GTBP Comparison
SOS vs GTBP Comparison
Compare SOS & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOS | GTBP |
|---|---|---|
| Founded | 2004 | 1965 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 12.4M |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SOS | GTBP |
|---|---|---|
| Price | $0.20 | $4.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 213.5K | 57.2K |
| Earning Date | 10-07-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.22 |
| 52 Week High | $2.08 | $287.50 |
Technical Indicators
Market Signals| Indicator | SOS | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 31.10 |
| Support Level | N/A | $0.22 |
| Resistance Level | $0.24 | $7.73 |
| Average True Range (ATR) | 0.02 | 0.52 |
| MACD | 0.01 | 0.22 |
| Stochastic Oscillator | 22.22 | 0.91 |
Price Performance
Historical ComparisonAbout SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.